2016 NCRI Cancer Conference
6-9 November, Liverpool, UK
Wednesday News

We have now come to the end of another extraordinary Conference. To those of you who were here in Liverpool with us, we thank you for making the 2016 NCRI Cancer Conference a great success and we look forward to welcoming you all to next year's Conference in Liverpool from 5-8 November 2017. 

Below you will find the latest news, highlights, photos from today, a link to our feedback survey and a preview of the 2017 programme.

NCRI 2016: Latest press releases
NCRI 2016: Wednesday highlights from the NCRI bloggers

Strategies to enable more efficient clinical trials
Lucinda Billingham, University of Birmingham, hosted one of this morning's parallel sessions, on strategies to enable more efficient clinical trials. Lucinda dedicated this session to Dan Sargent, Mayo Biostatistician and Clinical Trialists, who sadly recently passed away.
James Wason, University of Cambridge, kicked off the session, discussing how the efficacy of phase II oncology trials can be improved using augmented RECIST endpoints. Lucinda spoke on behalf of Richard Simon, National Cancer Institute, USA, about the new era of trial design in stratified medicine, covering umbrella trials (trials including patients with a single tumour type but with multiple mutations) and basket trials (trials including patients with multiple tumour types and multiple mutation). Tomasz Burzykowski, Hasselt University, Belgium, spoke about tumour size as a surrogate for overall survival in advanced colorectal cancer.  
Dominic Rothwell, CRUK Manchester Institute, and Gary Middleton, University of Birmingham, described the TARGET trial and the National Lung Matrix Trial, respectively.

Opportunities for step changes in the cancer landscape through health informatics

Three speakers discussed very different topics in this session, all united by one theme - the need to combine a variety of datasets to impact on patient outcomes. 
Morten Andersen explained the complexities of combining health data from multiple countries. Combining data increases the power and validity of the subsequent analysis, allowing rare events and association to be uncovered. Further developments in logistics, data management and statistical design are now needed to transform data into a single model. 

Philip Quinlan outlined his role in developing the Tissue Directory and Coordination Centre. He is linking biobanks across the country together to maximise the use of biobanks as a data resource for use in scientific research. 

Finally, Kathy Pritchard-Jones spoke about the need for data to inform and develop best practice in patient pathways. This work focusses on developing integrated pathway cancer intelligence to drive up standards and impact on patient outcomes.

Understanding responses to cancer therapy: The tissue is the issue but the scoop is in the poop

For the final plenary, Jennifer Wargo joined us from the MD Anderson Cancer Centre to discuss her exciting new work that highlights the importance of tissue based analysis and the gut microbiome in cancer research.

Prognosis for melanoma patients has improved markedly since the introduction of new immunotherapies. However not all patients respond to these therapies and it is increasingly important for us to be able to predict which patients will or will not respond to these treatments. Jennifer spoke about new data emerging from her lab that can use information about what microorganisms live in a patients gut (known as the microbiome) to predict their response to treatment. There is growing awareness of the role of the microbiome in health and disease, as well as its role in response to cancer therapy, and Jennifer predicts that it will become increasingly relevant in the coming years. As Jennifer says, "the scoop is in the poop"!

Tuesday highlight: How we talk about cancer
Powerful war analogies dominate how we talk about cancer, but are they appropriate? This thought provoking session included a group of speakers who eloquently described how the sometimes aggressive, often militaristic terms we use when speak about cancer can have a negative impact. 
Studies show that war analogies are good fund-raising mantras, but can have a negative affect when we are trying to encourage behavioural change to improve cancer prevention. And when it comes to individual patients, many do not feel comfortable with cancer as the 'enemy' finding themselves in a 'fight against self' and prefer to think of their cancer as an unwelcome visitor who will one day leave, albeit ushered out by a surgeon or healthcare professional, and possibly keeping the key to the door. 
Wednesday photos
Capture the full Conference - view the photo gallery

Your feedback helps us tremendously when planning future Conferences. Please take a few minutes to complete the online survey linked below. 

CPD Certificates

The 2016 NCRI Cancer Conference has been approved by the Federation of the Royal Colleges of Physicians for 24 category 1 (external) CPD credits. Please complete the appropriate section of the electronic Conference survey to request your electronic certificate. This may take up to 10 working days.
NCRI 2017 - We look forward to seeing you in Liverpool next year!

Confirmed speakers so far:
  • Jerome Galon, Intergrative Cancer Immunology Laboratory, INSERM, France
  • Steve Jackson, University of Cambridge, UK
  • Arul Chinnaiyan, Michigan Center for Translational Pathology, USA
  • Anthony Zeitman, Dana Farber Harvard Cancer Center, USA
  • Matt Ellis, Baylor College of Medicine, Houston, USA
  • Ton Schumacher, Netherlands Cancer Institute
  • Irene Higginson, Cicely Saunders Institute, Kings College London, UK
  • Annie Anderson, Centre for Public Health Nutrition Research and Centre for Research into Cancer Preventions and Screening, University of Dundee
  • Bin Tean Teh, DUKE-NUS Medical School, Singapore

Follow us on Twitter  View our profile on LinkedIn  View our videos on YouTube